OTCMKTS:CYDY CytoDyn (CYDY) Stock Price, News & Analysis $0.14 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.14▼$0.1450-Day Range$0.13▼$0.3052-Week Range$0.13▼$0.42Volume746,827 shsAverage Volume2.60 million shsMarket Capitalization$150.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get CytoDyn alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About CytoDyn Stock (OTCMKTS:CYDY)CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Read More CYDY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYDY Stock News HeadlinesJuly 9, 2024 | globenewswire.comCytoDyn Announces Settlement with Amarex Clinical Research LLCJune 27, 2024 | globenewswire.comCytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 28, 2024 | globenewswire.comCytoDyn to Host Webcast to Provide Company UpdateMay 16, 2024 | globenewswire.comMay 2024 Letter to ShareholdersFebruary 29, 2024 | markets.businessinsider.comCytoDyn Says FDA Lifts Hold On LeronlimabFebruary 29, 2024 | msn.comFDA lifts clinical hold on CytoDyn drug, stock rallies 22%February 29, 2024 | globenewswire.comCytoDyn Announces FDA Has Lifted Clinical HoldJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.February 10, 2024 | morningstar.comCytoDyn Inc CYDYFebruary 1, 2024 | markets.businessinsider.comCytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical StudyFebruary 1, 2024 | finance.yahoo.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFebruary 1, 2024 | tmcnet.comCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaJanuary 31, 2024 | bizjournals.comInvestors file another lawsuit against CytoDynJanuary 30, 2024 | msn.comCytoDyn Releases Regulatory FD Disclosure InformationJanuary 30, 2024 | msn.comCytoDyn Announces Executive Leadership Changes and AppointmentsJanuary 29, 2024 | bizjournals.comVancouver biotech appoints new CEO, as former top executive awaits fraud trialJanuary 29, 2024 | finanznachrichten.deCytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFOSee More Headlines Receive CYDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/13/2021Today7/26/2024Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYDY Previous SymbolNASDAQ:CYDY CUSIP23283M101 CIK1175680 Webwww.cytodyn.com Phone(360) 980-8524FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-478.47% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$270,000.00 Price / Sales556.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-1.18Miscellaneous Outstanding Shares1,061,950,000Free Float1,050,554,000Market Cap$150.27 million OptionableNot Optionable Beta0.14 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Cyrus Arman M.B.A. (Age 42)Ph.D., Senior Vice President of Business Operations Comp: $451.17kDr. Jacob P. Lalezari M.D. (Age 64)CEO & Member of Scientific Advisory Board Mr. Mitchell Cohen (Age 67)Interim Chief Financial Officer Mr. Tyler Blok (Age 36)Executive Vice President of Legal Affairs & Secretary Dr. Scott Hansen Ph.D.Head of Research & Basic ScienceMr. Joseph MeidlingExecutive Director of Clinical OperationsMs. Cristina De LeonInvestorsMore ExecutivesKey CompetitorsAlumisNASDAQ:ALMSCassava SciencesNASDAQ:SAVAVectivBioNASDAQ:VECTY-mAbs TherapeuticsNASDAQ:YMABBasilea PharmaceuticaOTCMKTS:BPMUFView All Competitors CYDY Stock Analysis - Frequently Asked Questions How have CYDY shares performed this year? CytoDyn's stock was trading at $0.1950 at the beginning of 2024. Since then, CYDY shares have decreased by 27.2% and is now trading at $0.1419. View the best growth stocks for 2024 here. How were CytoDyn's earnings last quarter? CytoDyn Inc. (OTCMKTS:CYDY) posted its earnings results on Tuesday, April, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. How do I buy shares of CytoDyn? Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CytoDyn own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT) and Nokia Oyj (NOK). This page (OTCMKTS:CYDY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.